Ben Veghte


WASHINGTON, DC – The National Venture Capital Association (NVCA) issued the following statement today in support of the nomination of Scott Gottlieb, M.D. for Commissioner of the Food and Drug Administration (FDA).  A Resident Fellow at the American Enterprise Institute (AEI), Gottlieb has deep experience in the venture industry, having previously served as a venture partner in life sciences startups at New Enterprise Associates (NEA).

“Through his experiences in public service, as a practicing physician and as an investor in healthcare startups, Dr. Gottlieb has been on the front lines of medical innovation for decades,” said Bobby Franklin, President and CEO of NVCA.  “Dr. Gottlieb has developed a keen understanding of the steps we need to take to ensure the U.S. continues to have a thriving medical innovation ecosystem.  We congratulate Dr. Gottlieb on his nomination and look forward to working with him to improve the regulatory environment so that U.S. continues to be the tip of the spear in developing solutions to diagnose, treat and cure some of the deadliest and most costly diseases.”

About National Venture Capital Association

Venture capitalists are committed to funding America’s most innovative entrepreneurs, working closely with them to transform breakthrough ideas into emerging growth companies that drive U.S. job creation and economic growth. As the voice of the U.S. venture capital community, the National Venture Capital Association (NVCA) empowers its members and the entrepreneurs they fund by advocating for policies that encourage innovation and reward long-term investment. As the venture community’s preeminent trade association, the NVCA serves as the definitive resource for venture capital data and unites its member firms through a full range of professional services. For more information about the NVCA, please visit